PAG
CRBP icon

Private Advisor Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Private Advisor Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-82
Closed -$21K – 1924
2020
Q2 		$21K Buy
+82
New +$16.6K ﹤0.01% 2537
2017
Q4 		– Sell
-458
Closed -$97K – 1218
2017
Q3 		$97K Buy
+458
New +$89.6K ﹤0.01% 1413
2017
Q2 		– Sell
-600
Closed -$140K – 1395
2017
Q1 		$140K Sell
600
-233
-28% -$57.2K ﹤0.01% 1328
2016
Q4 		$201K Buy
+833
New +$191K 0.01% 1154

Other funds holding CRBP

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Private Advisor Group's CRBP Position: Q3 2020 in Review

Private Advisor Group sold out of Corbus Pharmaceuticals (CRBP) in Q3 2020, closing a stake of 82 shares — an estimated $21K sold.

Private Advisor Group first reported a position in CRBP in Q4 2016 and held it in 4 quarters. The position peaked at $201K in Q4 2016. 122 funds tracked by Wall St. Rank hold CRBP as of Q3 2020.

  • Private Advisor Group reported no remaining Corbus Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 82 Corbus Pharmaceuticals shares in Q3 2020, an estimated $21K.
  • Private Advisor Group first reported a position in Corbus Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • Private Advisor Group's Corbus Pharmaceuticals position peaked at $201K in Q4 2016.
  • 122 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.